Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207024 | 0.81 | LMNA (0.52) | AKR1B1KCNH2HSD11B1LMNAMAPT | |
| SCHEMBL6206245 | 0.81 | AKR1B1 (0.53) | AKR1B1LMNAMAPTKMT2AALDH1A1 | |
| SCHEMBL6229563 | 0.74 | AKR1B1 (0.47) | AKR1B1HTR2AKCNH2HSD11B1LMNA | |
| SCHEMBL6205585 | 0.74 | AKR1B1 (0.54) | AKR1B1LMNAMAPTKMT2ACNR2 | |
| SCHEMBL4450397 | 0.72 | NNMT (0.41) | LMNAMAPTALDH1A1SMN1; SMN2EDNRA | |
| SCHEMBL6206045 | 0.72 | LMNA (0.47) | AKR1B1LMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL30333632 | 0.71 | AKR1B1 (0.53) | AKR1B1HTR2AHTR2CHSD11B1KMT2A | |
| SCHEMBL250919 | 0.71 | AKR1B1 (0.53) | AKR1B1HTR2AHTR2CHSD11B1KMT2A | |
| SCHEMBL2124755 | 0.71 | AKR1B1 (0.53) | AKR1B1HTR2AHTR2CHSD11B1KMT2A | |
| SCHEMBL6642836 | 0.69 | TXNRD1 (0.33) | AKR1B1LMNAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236720-B1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6872722-B2 | Therapies for tissue damage resulting from ischemia | PFIZER INC (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1260224-B1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | PFIZER PROD INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | MYLARI BANAVARA L (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1260224-A1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1236720-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | AKR1B1 2/4885CYP11B1 85/4885CYP11B2 53/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | AKR1B1 3/4885CYP11B1 88/4885CYP11B2 45/4885 |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | TNNI3, TNNC1, TNNT2 | AKR1B1 2046/4885CYP11B1 3295/4885CYP11B2 3222/4885 |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | ALDOA, PDXK, AKR1B1 | AKR1B1 3/4885CYP11B1 277/4885CYP11B2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.